Why NightHawk Biosciences Stock Is Soaring

NightHawk Biosciences Inc NHWK shares are trading higher Monday after the company said it would fund development of a monkeypox vaccine.

NightHawk executed a research and development license agreement with Lytic Solutions on Sunday.  As part of the agreement, NightHawk will fund a research program for development of a proprietary subunit monkeypox vaccine.

The Lytic platform has exhibited immunogenicity and vaccine success against other viral targets in non-human primates. NightHawk will own all monkeypox virus construct sequences conceived, developed or reduced to practice during the research program. These new constructs will be targeted against a series of proteins to formulate a polyclonal vaccine.

NightHawk is a commercial-stage company with a fully integrated ecosystem to accelerate the discovery and development of novel therapies that arm the immune system.

See Also: AMC Entertainment Stock Is Going APE Today: What's Going On?

NWHK Price Action: NightHawk has a 52-week high of $3.17 and a 52-week low of $1.60.

The stock was up 18.1% at $2.68 at press time, according to Benzinga Pro.

Photo: PublicDomainPictures from Pixabay.